New Risk • Mar 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2024 fiscal period end). Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). 공시 • Mar 14
Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 30, 2026 Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 60, haan-ro, gyeonggi-do, gwangmyeong South Korea New Risk • Nov 14
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2024 fiscal period end). Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$98.9m). New Risk • Sep 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 68% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩123.2b market cap, or US$88.5m). 공시 • Aug 20
Kangstem Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 36.632 billion. Kangstem Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 36.632 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 38,000,000
Price\Range: KRW 964
Discount Per Security: KRW 12.532
Transaction Features: Rights Offering New Risk • Jul 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₩79.7b market cap, or US$57.9m). 공시 • Jun 11
Kangstem Biotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 49.21 billion. Kangstem Biotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 49.21 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 38,000,000
Price\Range: KRW 1295
Discount Per Security: KRW 16.835
Transaction Features: Rights Offering New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₩113.5b market cap, or US$82.2m). 공시 • Feb 27
Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 26, 2025 Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 60, haan-ro, gyeonggi-do, gwangmyeong South Korea New Risk • Nov 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (48% increase in shares outstanding). Market cap is less than US$100m (₩106.6b market cap, or US$76.5m). 공시 • Apr 26
An undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. (KOSDAQ:A217730) for KRW 2.8 billion An undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. (KOSDAQ:A217730) for KRW 2.8 billion on April 25, 2024. Reported Earnings • Mar 16
Full year 2023 earnings released: ₩541 loss per share (vs ₩533 loss in FY 2022) Full year 2023 results: ₩541 loss per share (further deteriorated from ₩533 loss in FY 2022). Revenue: ₩12.7b (down 22% from FY 2022). Net loss: ₩21.9b (loss widened 8.5% from FY 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. New Risk • Nov 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (47% increase in shares outstanding). Market cap is less than US$100m (₩75.2b market cap, or US$58.4m). New Risk • Nov 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 5.4% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩61.2b market cap, or US$47.2m). New Risk • Aug 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.2% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩80.0b market cap, or US$59.9m). Reported Earnings • Mar 19
Full year 2022 earnings released: ₩533 loss per share (vs ₩767 loss in FY 2021) Full year 2022 results: ₩533 loss per share (improved from ₩767 loss in FY 2021). Revenue: ₩16.3b (up 31% from FY 2021). Net loss: ₩20.2b (loss narrowed 5.2% from FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Non-executive Director Jung-Ho Choi was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 18
Second quarter 2022 earnings released: ₩125 loss per share (vs ₩162 loss in 2Q 2021) Second quarter 2022 results: ₩125 loss per share. Revenue: ₩3.94b (up 51% from 2Q 2021). Net loss: ₩4.76b (loss widened 15% from 2Q 2021). Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Non-executive Director Jung-Ho Choi was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Is New 90 Day High Low • Feb 24
New 90-day low: ₩6,850 The company is down 4.0% from its price of ₩7,150 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Sep 22
New 90-day low: ₩7,340 The company is down 31% from its price of ₩10,600 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period.